<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01654497</url>
  </required_header>
  <id_info>
    <org_study_id>111827</org_study_id>
    <nct_id>NCT01654497</nct_id>
  </id_info>
  <brief_title>Dexanabinol in Patients With Brain Cancer</brief_title>
  <official_title>A Phase I, Sequential Cohort, Open-Label, Dose-escalation Study of the Safety and CNS Pharmacokinetics of Dexanabinol in Patients With Brain Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santosh Kesari, M.D., Ph.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>e-Therapeutics PLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to try to determine the maximum safe dose of dexanabinol that&#xD;
      can be administered to people with brain cancer. Other purposes of this study are to:&#xD;
&#xD;
        -  find out what effects (good and bad) dexanabinol has;&#xD;
&#xD;
        -  see how much drug gets into the body by collecting blood and cerebrospinal fluid for use&#xD;
           in pharmacokinetic (PK) studies;&#xD;
&#xD;
        -  learn more about how dexanabinol might affect the growth of cancer cells;&#xD;
&#xD;
        -  look at biomarkers (biochemical features that can be used to measure the progress of&#xD;
           disease or the effects of a drug).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protection from apoptosis is a key survival factor for cancer cells. Dexanabinol is under&#xD;
      investigation as a novel anti-cancer therapy based on its tumoricidal activity observed in&#xD;
      vitro and in vivo, presumably due to inhibitory activity against NFĸB, TNFα, COX-2 and&#xD;
      additional putative targets suck as HAT, FAT and cyclin dependent kinases. Targeted induction&#xD;
      of apoptosis in cancer cells versus normal cells provides an attractive strategy for the&#xD;
      treatment of brain cancer, a pernicious disease with debilitating neurological side effects&#xD;
      and poor prognoses. A single intravenous dosing of dexanabinol has demonstrated safety in&#xD;
      humans. Therefore, we are conducting a phase I dose escalation study to examine the safety of&#xD;
      multiple dosing of dexanabinol and drug penetration into the brain, and to determine a&#xD;
      suitable dose for moving into a phase II trial for efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of dose limiting toxicities and the maximum tolerated dose (MTD) of weekly dexanabinol</measure>
    <time_frame>first 28 days of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events</measure>
    <time_frame>7 months</time_frame>
    <description>description, timing, grade [CTCAE v4.03], severity, seriousness, and relatedness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate and best overall response rate over time as assessed by the RANO criteria</measure>
    <time_frame>approximately 6 months to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Brain Cancer</condition>
  <arm_group>
    <arm_group_label>Dexanabinol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexanabinol</intervention_name>
    <description>Dexanabinol: intravenous infusion over 3 hours, weekly (i.e., Day 1, 8, 15 and 22 of a 28-day cycle)&#xD;
Nine dosing cohorts are planned, with the option to enroll additional cohorts based on safety and PK data.&#xD;
Dose Level 1: 2 mg/kg&#xD;
Dose Level 2: 4 mg/kg&#xD;
Dose Level 3: 8 mg/kg&#xD;
Dose Level 4: 16 mg/kg&#xD;
Dose Level 5: 24 mg/kg&#xD;
Dose Level 6: 28 mg/kg&#xD;
Dose Level 7: 36 mg/kg&#xD;
Dose Level 8: 40 mg/kg&#xD;
Dose Level 9: 44 mg/kg</description>
    <arm_group_label>Dexanabinol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or radiologically confirmed diagnosis of brain cancer:&#xD;
&#xD;
               -  glioblastoma (GBM),&#xD;
&#xD;
               -  anaplastic astrocytoma (AA),&#xD;
&#xD;
               -  anaplastic oligodendroglioma (AO),&#xD;
&#xD;
               -  anaplastic mixed oligoastrocytoma (AMO),&#xD;
&#xD;
               -  low grade gliomas,&#xD;
&#xD;
               -  brain metastases,&#xD;
&#xD;
               -  meningiomas, or&#xD;
&#xD;
               -  leptomeningeal metastases&#xD;
&#xD;
          -  Has failed prior standard therapy including maximal safe surgical resection, radiation&#xD;
             therapy (when appropriate for the specific cancer type), and systemic therapy.&#xD;
&#xD;
          -  For diagnosis of GBM: has undergone at least one prior surgical gross-total or&#xD;
             subtotal tumor resection, a course of postoperative radiation therapy with concurrent&#xD;
             temozolomide, and at least 2 cycles of maintenance temozolomide.&#xD;
&#xD;
          -  For diagnosis of meningioma: has no other option of standard therapy such as surgical&#xD;
             resection (partial or total resection) or radiation.&#xD;
&#xD;
          -  Has progression of brain cancer and measurable disease by magnetic resonance imaging&#xD;
             (MRI) or computed tomography (CT) scan.&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Karnofsky Performance Status ≥ 60%. (Appendix A). Subjects must have a life expectancy&#xD;
             of equal to or greater than 8 weeks.&#xD;
&#xD;
          -  Organ and Marrow Function Requirements&#xD;
&#xD;
        Hematology:&#xD;
&#xD;
          -  Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L&#xD;
&#xD;
          -  Platelet count ≥ 100 x 109/L&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  White blood cell (WBC) count ≥ 3.0 x 109/L&#xD;
&#xD;
        Biochemistry:&#xD;
&#xD;
          -  AST/SGOT and ALT/SGPT ≤ 2.5 x institution's ULN&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 x institution's ULN&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 x institution's ULN or 24-hour creatinine clearance ≥ 50 ml/min&#xD;
&#xD;
          -  Alkaline phosphatase (ALP) ≤ 2.5 x ULN unless considered tumor related&#xD;
&#xD;
          -  Estimated GFR &gt; 50 ml/min (based on Wright formula)&#xD;
&#xD;
        Coagulation:&#xD;
&#xD;
          -  INR &lt; 1.5 x institution's ULN&#xD;
&#xD;
          -  PT/aPTT within institution's normal range, unless receiving therapeutic low molecular&#xD;
             weight heparin&#xD;
&#xD;
               -  Contraception Woman of child-bearing potential and man with partners of&#xD;
                  child-bearing potential agrees to use adequate contraception (hormonal or barrier&#xD;
                  method of birth control; abstinence) prior to study entry, for the duration of&#xD;
                  study participation, and for 30 days following completion of therapy.&#xD;
&#xD;
               -  Woman of child-bearing potential has negative pregnancy test before the&#xD;
                  initiation of study drug dosing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or anticipated use of other investigational agents.&#xD;
&#xD;
          -  Current or anticipated use of enzyme-inducing anti-epileptic drugs (EIAED).&#xD;
&#xD;
          -  Insufficient time for recovery from prior therapy:&#xD;
&#xD;
               -  less than 28 days from any investigational agent,&#xD;
&#xD;
               -  less than 28 days from prior cytotoxic therapy (except 23 days from prior&#xD;
                  temozolomide, 14 days from vincristine, 42 days from nitrosoureas, 21 days from&#xD;
                  procarbazine administration), and&#xD;
&#xD;
               -  less than 7 days for non-cytotoxic agents, e.g., interferon, tamoxifen,&#xD;
                  thalidomide, cis-retinoic acid, etc. (radiosensitizer does not count).&#xD;
&#xD;
          -  Less than 4 weeks from surgery or insufficient recovery from surgical-related trauma&#xD;
             or wound healing.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to dexanabinol.&#xD;
&#xD;
          -  History of allergic reactions to medicines containing polyoxyethylated castor oil that&#xD;
             are not controlled with premedications.&#xD;
&#xD;
          -  Severe or uncontrolled medical disorder that would, in the investigator's opinion,&#xD;
             impair ability to receive study treatment (i.e., uncontrolled diabetes, chronic renal&#xD;
             disease, chronic pulmonary disease or active, uncontrolled infection).&#xD;
&#xD;
          -  Electrolyte abnormality that cannot be corrected to normal levels prior to initiating&#xD;
             study drug.&#xD;
&#xD;
          -  Known diagnosis of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  Impaired cardiac function including any of the following:&#xD;
&#xD;
               -  Congenital long QT syndrome or a known family history of long QT syndrome;&#xD;
&#xD;
               -  History or presence of clinically significant ventricular or atrial&#xD;
                  tachyarrhythmias&#xD;
&#xD;
               -  Clinically significant resting bradycardia (&lt; 50 beats per minute)&#xD;
&#xD;
               -  Inability to monitor the QT interval by ECG&#xD;
&#xD;
               -  QTc &gt; 450 msec on baseline ECG. If QTc &gt; 450 and electrolytes are not within&#xD;
                  normal ranges, electrolytes should be corrected and then the patient re-screened&#xD;
                  for QTc&#xD;
&#xD;
               -  Myocardial infarction within 1 year of starting study drug&#xD;
&#xD;
               -  Other clinically significant heart disease (e.g., unstable angina, congestive&#xD;
                  heart failure, or uncontrolled hypertension)&#xD;
&#xD;
          -  Pregnant or nursing. There is a potential for congenital abnormalities and for this&#xD;
             regimen to harm nursing infants.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Santosh Kesari, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0698</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 16, 2012</study_first_submitted>
  <study_first_submitted_qc>July 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2012</study_first_posted>
  <last_update_submitted>November 12, 2019</last_update_submitted>
  <last_update_submitted_qc>November 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Santosh Kesari, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Brain</keyword>
  <keyword>Glioma</keyword>
  <keyword>glioblastoma</keyword>
  <keyword>metastases</keyword>
  <keyword>cancer</keyword>
  <keyword>ETS2101</keyword>
  <keyword>leptomeningeal</keyword>
  <keyword>astrocytoma</keyword>
  <keyword>oligodendroglioma</keyword>
  <keyword>meningioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HU 211</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

